Published in final edited form as:

Trends Cell Biol. 2016 March ; 26(3): 165–176. doi:10.1016/j.tcb.2015.10.014.

Ferroptosis: death by lipid peroxidation

Wan Seok Yang^{1,*} and Brent R. Stockwell^{1,2,3,*}

¹Department of Biological Sciences, Howard Hughes Medical Institute, Columbia University, New York, NY, USA

²Department of Chemistry, Columbia University, New York, NY, USA

³Department of Systems Biology, Columbia University, New York, NY, USA

Abstract

Ferroptosis is a regulated form of cell death driven by loss of activity of the lipid repair enzyme glutathione peroxidase 4 (GPX4) and subsequent accumulation of lipid-based reactive oxygen species, particularly lipid hydroperoxides. This form of iron-dependent cell death is genetically, biochemically, and morphologically distinct from other cell death modalities, including apoptosis, unregulated necrosis, and necroptosis. Ferroptosis is regulated by specific pathways and is involved in diverse biological contexts. Here, we summarize the discovery of ferroptosis, the mechanism of ferroptosis regulation, and its increasingly appreciated relevance to both normal and pathological physiology.

Keywords

ferroptosis; GPX4; system x_c^- ; lipid peroxides; ROS; cell death

Discovery of ferroptosis

Cell death is essential for fundamental physiological processes, such as development, immunity, and tissue homeostasis; moreover, cell death is often dysregulated in degenerative and neoplastic diseases. Both apoptotic and non-apoptotic cell death modalities have increasingly been necessary to explain diverse biological processes involving cell loss. Two regulated forms of non-apoptotic cell death, necroptosis and ferroptosis, have been shown recently to play significant roles in numerous biological contexts [1, 2]. While the mechanisms and physiological relevance of necroptosis have been reviewed recently [3], we focus here on the molecular mechanisms controlling ferroptosis and its relevance to health and disease.

Corresponding authors: Yang, W.S. (yangw@stjohns.edu); Stockwell, B.R. (bstockwell@columbia.edu).

⁴Present address: Department of Biological Sciences, St. John's University, Queens, NY, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Early life on Earth developed in the absence of oxygen [4]; approximately 2.4 billion years ago, the composition of the atmosphere changed dramatically, likely due to oxygen production from emerging photosynthetic organisms [5, 6]. After this Great Oxygenation Event, oxygen in the atmosphere ultimately rose from only trace abundances to its current 21% abundance [5, 6]. The emergence of copious amounts of oxygen in the atmosphere was challenging for organisms with membranes having polyunsaturated lipids that contain bis-allylic carbons, because these are highly susceptible to lipid peroxidation in the presence of oxygen [7]. This peroxidation reaction is dramatically accelerated by divalent metals, especially Fe(II) [7].

While life probably originated using saturated amphiphilic lipids (*i.e.* charged, but hydrophobic molecules lacking carbon-carbon double bonds, such as simple fatty acids) [8], before long, monounsaturated and polyunsaturated lipids were integrated into lipid metabolism and membrane biochemistry, as they allow increased tunability of membrane fluidity [9]. However, the presence of these polyunsaturated fatty acids created a liability after the Great Oxygenation Event, especially because of the abundance of Fe(II) and Fe(II)-dependent enzymes—without a means to prevent lipid peroxidation, these membranes became the source of damaging oxidative species, as reactive lipid peroxides were generated.

These observations on the early origin and essential functions of polyunsaturated fatty, Fe(II)-dependent oxidation chemistry and abundant oxygen suggest the hypothesis that the evolution of defenses against lipid peroxidation was an early selective event in the development of life. Over time, this defense system was adapted to a more complex control mechanism that allowed fine-tuned control over lipid peroxidation, enabling it to be harnessed to generate signaling molecules (e.g. in the inflammatory cascade), suppressed to preserve cell integrity under high peroxidation stress (e.g., in neurons or renal tubules), or unleashed to cause lethal lipid peroxidation (e.g. in neoplastic cells).

Ferroptosis is this non-apoptotic, peroxidation-driven form of regulated cell death that requires abundant and accessible cellular iron; the existence of this ancient form of cell death was unknown and only discovered recently using a pharmacological approach [10]. The first ferroptosis-inducing compounds, erastin [11] and RSL3 [12], were discovered using high-throughput screening of small molecule libraries [11, 12]. The mode of cell death induced by these compounds was surprisingly found to be non-apoptotic, as cells treated with erastin and RSL3 died in the absence of apoptotic hallmarks [11, 12, 13], and in cells where the core apoptosis machinery – caspases, BAX, and BAK was suppressed [14]. Although non-apoptotic, erastin-induced cell death proceeds normally upon knockdown of RIPK1/RIPK3, or pharmacological inhibition of RIPK1 [10, 15, our unpublished data], known components of necroptosis [16]. Therefore, the cell death phenotype induced by erastin and RSL3 is distinct from other reported modalities, including apoptosis and necroptosis.

Further studies [13, 17] identified lipophilic antioxidants (α -tocopherol, butylated hydroxytoluene and β -carotene) as strong suppressors of erastin-induced cell death, suggesting that reactive oxygen species (ROS), likely lipophilic in nature, were involved in

this cell death process. Indeed, analysis with dichlorofluorescein (DCF), a ROS-detecting dye, revealed that erastin causes the generation of ROS in sensitive cell lines [10, 13]. Moreover, iron chelators were identified as inhibitors of cell death induction, after RSL3 treatment, revealing the requirement of cellular iron [12].

Using modulatory profiling, an unbiased pharmacological and genetic profiling system in which lethal compounds are classified based on their functional profiles [14, 18], erastin and RSL3 were found to cluster together, suggesting that they share a similar cell death mechanism. This erastin-RSL3 cluster is distinct from other lethal compounds that induce apoptosis and necrosis. Taken together, the mode of cell death induced by erastin, RSL3 and related compounds was proposed to be a previously unrecognized form of cell death termed ferroptosis (ferro = “ferrous ion (Fe^{2+})”, ptosis = “fall”), suggesting a critical role for cellular iron in this regulated form of oxidative cell death [10].

Mechanism of ferroptosis induction by erastin and RSL3

Key regulators of ferroptosis have been discovered through characterizing the mechanism of action of erastin and RSL3, using multi-pronged approaches (Figure 1, Key Figure).

Ferroptosis induction by system x_c^- inhibition

Glutamate-induced toxicity can be initiated by calcium influx after glutamate receptor activation [19], or by competitive inhibition of system x_c^- , the glutamate/cystine antiporter [20, 21] (Box 1). Glutamate-induced neurotoxicity is an oxidative, iron-dependent process, suggesting that ferroptosis is involved [22, 23]. Calcium chelators showed no effect on erastin-induced cell death [14], suggesting that glutamate receptor activation is not involved. In addition, modulatory profiles of erastin and sulfasalazine (SAS), an inhibitor of system x_c^- , were similar to each other, suggesting that erastin might act as a system x_c^- inhibitor to initiate ferroptosis [10]. Indeed, erastin treatment abolished the import of radiolabeled cystine [10], a substrate for the system x_c^- antiporter, confirming that erastin inhibits system x_c^- .

One metabolic consequence of system x_c^- inhibition is depletion of the intracellular cysteine pool, which is a precursor for glutathione synthesis. Indeed, a metabolite profiling assay revealed that glutathione was the most decreased cellular metabolite during erastin-induced ferroptosis [24]. This glutathione depletion is sufficient for erastin-dependent cell death, as glutathione depletion by another reagent, buthionine sulfoxamine (BSO), also initiated ferroptosis [24]. BSO is an inhibitor of glutamate-cysteine ligase, the rate-limiting enzyme for glutathione synthesis. Glutathione depletion causes loss of cellular antioxidant capacity, as well as inhibition of glutathione-dependent enzymes, such as glutathione peroxidases [24, 25].

Direct inhibition of GPX4 by RSL3

Cell death induced by RSL3 shares common features with erastin-mediated ferroptosis, such as iron, MEK, and ROS dependencies [12]. However, RSL3 treatment does not prevent the import of radiolabeled cystine, indicating that RSL3 does not inhibit system x_c^- [10].

Moreover, glutathione is not depleted during RSL3-induced cell death [24], supporting the presence of an alternative ferroptosis-initiating mechanism for RSL3.

Analysis of mass spectrometry-based proteomic data from an affinity pulldown experiment ranked GPX4 (glutathione peroxidase 4, PHGPx) as the top protein target for (1*S*,3*R*)-RSL3 [24]; western blotting further confirmed binding between (1*S*,3*R*)-RSL3 and GPX4. Cell lysates prepared from (1*S*, 3*R*)-RSL3-treated cells could not reduce phosphatidylcholine hydroperoxides into the corresponding alcohols, demonstrating that RSL3 inhibits GPX4 enzyme activity [24]. Moreover, knockdown of GPX4 expression generates lipid ROS and induces ferroptosis, supporting the hypothesis that (1*S*, 3*R*)-RSL3 induces ferroptosis through inhibition of GPX4 [24].

The identification of GPX4 as the target protein for RSL3 is intriguing for two reasons. First, GPX4 is the only enzyme that can reduce lipid hydroperoxides within biological membranes [25]. This explains why cells treated with RSL3 display elevated lipid ROS during ferroptosis in the absence of GSH depletion. The strong protective effect of lipophilic antioxidants, such as vitamin E, is likely due to their ability to suppress the formation and propagation of oxidized lipids upon GPX4 inhibition. Second, GPX4 uses glutathione as an essential cofactor for its enzymatic activity [25]. As erastin inhibits system x_c^- and depletes glutathione, the result is that erastin inhibits GPX4 in an indirect manner, which explains how erastin and RSL3 share a common cell death execution mechanism, but different triggering mechanisms (Figure 1).

Emerging ferroptosis-inducing compounds and mechanisms

Additional ferroptosis-inducing compounds and mechanisms have been identified, and are broadly categorized as system x_c^- inhibitors, glutathione depleters or direct GPX4 inhibitors.

Induction of Ferroptosis by DPI compounds

The screening assay in which erastin and RSL3 were identified later revealed ten additional compounds that induce ferroptosis [24, 26]. All but one compound (DPI2) inhibited GPX4 directly, similar to RSL3. In contrast, DPI2 depleted GSH, like erastin [24]. Overexpression of GPX4 suppressed cell death induced by these compounds [24], but not other lethal agents, indicating that GPX4 is a specific and robust central regulator of ferroptotic cell death, akin to BCL-2 in apoptosis.

System x_c^- inhibition by sorafenib

Sorafenib, a multi-kinase inhibitor, is an FDA-approved drug used for treating advanced renal cell carcinoma and advanced hepatocellular carcinoma (HCC). In HCC cell lines, sorafenib was reported to induce a non-apoptotic form of cell death that was suppressed by lipophilic antioxidants [27, 28], indicating that sorafenib activates ferroptosis in HCC cell lines. Indeed, sorafenib acts as an inhibitor of system x_c^- , similar to erastin [29]. The adverse event profile of sorafenib in patients was found to be consistent with the notion that sorafenib exerts additional activity *in vivo* compared to other similar kinase inhibiting drugs that do not inhibit system x_c^- [29]. Recently, the retinoblastoma protein (Rb) was found to

suppress ferroptosis in response to sorafenib [30], suggesting that Rb status may aid in selecting ferroptosis-sensitive tumors, at least for sorafenib.

Ferroptosis induction by FIN56

CIL56 and FIN56 are small molecules discovered from a systematic survey of non-apoptotic cell death mechanisms [31]. CIL56-induced and FIN56-induced cell death is accompanied by lipid-ROS generation; vitamin E and iron chelators suppressed cell death induced by these compounds [31], confirming that they are ferroptosis inducers. Cells treated with FIN56 maintained GSH levels, indicating that, unlike erastin, FIN56 is not a system x_c^- inhibitor. Instead, FIN56 treatment resulted in loss of GPX4 protein through post-translational degradation, and blocked mevalonate-derived production of lipophilic antioxidants, such as coenzyme Q₁₀ (Figure 1). While FIN56 acts solely as a ferroptosis inducer, CIL56 also activates a non-ferroptotic mechanism at higher concentrations and is dependent on ACC1 (acetyl-CoA carboxylase alpha) [32].

Pathways modulating ferroptosis

Mevalonate pathway

Selenoprotein biosynthesis is regulated by the mevalonate pathway. GPX4 is a selenoprotein that contains selenocysteine (Sec) in the active site of the enzyme (Figure 1). The genetic code for Sec is UGA, which is normally a stop codon; therefore, it requires dedicated translational machinery to incorporate Sec into the internal UGA codon of GPX4. The selenocysteine-tRNA (tRNA(Sec)), is one of the key components of the machinery and controls the biosynthesis of all 25 selenoproteins present in humans [33]. tRNA(Sec) undergoes lipid modification (isopentenylation) at a specific adenine site during the maturation process, which is required for efficient Sec incorporation into selenoproteins. The enzyme that carries out this modification, tRNA isopentenyl transferase, uses isopentenyl pyrophosphate as a donor. As isopentenyl pyrophosphate is a product of the mevalonate pathway, inhibitors of the mevalonate pathway, such as statins, have been shown to interfere with tRNA(Sec) maturation and the biosynthesis of GPX4 in cell culture [34]. The efforts to target the mevalonate pathway in several human diseases, including hypercholesterolemia, osteoporosis, and cancer, suggest that further investigation into the modulation of ferroptosis by the mevalonate pathway is warranted.

The transsulfuration pathway

Cysteine is a non-essential amino acid, because some mammalian cells are able to synthesize cysteine through the transsulfuration pathway, in which methionine is used as a sulfur donor and is converted into cysteine through the intermediates homocysteine and cystathionine [35]. In addition to synthesizing cysteine *de novo*, cells can take up extracellular cysteine in the form of cystine, the oxidized disulfide, using transporters such as system x_c^- and EAATs (excitatory amino-acid transporters) to provide the cysteine required for protein synthesis and detoxification of oxidative stress [36].

The relative importance of transsulfuration versus uptake mechanisms is cell-type dependent under normal conditions. The transsulfuration pathway becomes important for cell survival

when the uptake mechanism is inhibited. A genome-wide RNA interference screen revealed siRNAs targeting *CARS* (cysteinyl-tRNA synthetase) as robust genetic suppressors of erastin-induced ferroptosis [37]. Both genes and metabolites in the transsulfuration pathway, such as cystathionine and cysteine, were upregulated in *CARS*-depleted cells treated with erastin [37] (Figure 1). Thus, the transsulfuration pathway is a regulator of ferroptosis; ferroptosis inducers such as erastin that block cystine uptake might be preferentially lethal to cancer cells with a defective transsulfuration pathway.

Additional pathways regulating ferroptosis

Several additional pathways have been reported to modulate ferroptosis. Glutamine and transferrin were found to induce ferroptosis under serum-deprivation conditions, via the glutaminolysis pathway [38, 39]. Moreover, inhibiting glutaminolysis was protective in a model of ischemia-reperfusion-induced heart injury, suggesting this is an additional strategy and indication for suppressing ferroptosis. Acetaminophen has been reported to induce ferroptosis in primary hepatocytes via glutathione depletion [40], suggesting this may be a mechanism of drug-induced toxicity. Finally, heat shock protein beta 1 (HSPB1) was reported to suppress ferroptosis through an unknown mechanism [41]; this suggests that heat shock proteins may be important in setting the sensitivity to ferroptosis in some cell contexts.

Role of ferroptosis in development

Recent *in vivo* and clinical studies of components of ferroptosis are beginning to reveal a role for this cell death process in development. Knockout of *Gpx4* in mice caused embryonic lethality between E7.5 and E8.5, indicating an essential role of *Gpx4* in mouse development [42, 43]. An inducible *Gpx4* knockout mouse model demonstrated that some cells and tissues, particularly neurons in the brain, accumulate lethal lipid ROS that can be alleviated by vitamin E treatment [44], highlighting the lethal nature of lipid peroxidation *in vivo* in the absence of *Gpx4*. Moreover, a recent study found that conditional ablation of *Gpx4* in neurons in mice caused selective and rapid motor neuron degeneration via ferroptosis, and ultimately onset of paralysis [45]; this suggests that ferroptosis may drive some types of motor neuron disease, and its suppression is perhaps critical in motor neuron development and homeostasis. No hallmark of apoptosis could be detected in the dying cells of *Gpx4*^{-/-} mice [44], and analysis of the same animal model confirmed that the lethal phenotype is driven by ferroptosis [15]. Tubular cells in the kidney are also particularly susceptible to ferroptosis induction by *Gpx4* deletion *in vivo* [15], which is intriguing in light of the enhanced sensitivity of renal cell carcinoma cell lines in culture to erastin [24]. In addition, conditional deletion of *Gpx4* in T cells in mice resulted in T cell ferroptosis, resulting in lack of an immune response to infection [46]; this suggests that *Gpx4* is essential for a functional T-cell-mediated immune response.

In addition to causing embryonic lethality upon loss of *Gpx4*, ferroptosis may be involved in the normal developmental process of mammalian limb development. During development in mammals, interdigital webbing is removed by activation of programmed cell death processes to sculpt the digits [47]. In addition to the presence of apoptotic markers in these interdigital dying tissues, ROS levels are elevated and *Gpx4* expression levels are reduced,

suggesting activation of ferroptosis [48]. While the limbs of *Gpx4* transgenic mice do develop normally, possibly arguing against the role of ferroptosis in this process [49], overexpression of *Gpx4* would not likely be sufficient to overcome glutathione depletion; moreover, the *Gpx4* transgene may not be activated in this tissue context and suppression of the ferroptosis phenotype *in vivo* may require engineering of multiple ferroptosis regulatory genes. By analogy, the limbs of mice lacking *Bak* develop normally, whereas mice lacking both *Bax* and *Bak* fail to achieve a sufficient level of physiological cell death and display persistent interdigital webbing [50].

Connections to human disease

The importance of ferroptosis in development is also evident clinically [51]. Sedaghatian-type spondylometaphyseal dysplasia is a neonatal lethal form of spondylometaphyseal dysplasia, a bone growth disorder, and is inherited in an autosomal recessive manner [52]. Whole exome sequencing of an affected child and its family identified point mutations in *GPX4* that caused premature truncation of the GPX4 protein, which results in the lack of GPX4 enzyme activity [53]. Numerous other ferroptosis-disease associations are summarized in Table 1.

The role of ferroptosis in a variety of pathophysiological settings has been evaluated using ferrostatin-1 (Fer-1), a small molecule inhibitor of ferroptosis. Ferrostatin-1 acts as a lipid ROS scavenger and prevents ferroptosis induced by erastin and RSL3, but does not suppress cell death induced by staurosporine (an apoptosis inducer) or hydrogen peroxide (an oxidative necrosis inducer) [10].

Acute kidney injury

Rhabdomyolysis is the breakdown of muscle tissue due to either direct or indirect muscle injury [54]. Breakdown products, including myoglobin, enter circulation and damage sensitive tissues, such as the kidney, causing acute organ damage, such as kidney failure. Iron released from the heme of myoglobin generates reactive oxygen species and damages kidney cells [55]. Administration of hydroxyquinoline and ferrous ammonium sulfate to freshly isolated mouse kidney proximal tubules simulates major elements of rhabdomyolysis-induced acute kidney injury [56]. Using this model, ferrostatin-1 prevented cell death in kidney proximal tubules, suggesting the necessity of ferroptosis for rhabdomyolysis-induced acute kidney injury [57]. In addition, ferrostatin-1 prevented the synchronized death of renal tubules and oxalate-crystal-induced acute kidney injury [58]. SRS16-86 is a third generation ferrostatin with increased plasma and metabolic stability; in an *in vivo* model of renal ischemia-reperfusion injury, SRS16-86 protected kidney function and extended mouse survival after ischemia-reperfusion injury [58].

Liproxstatin-1, a spiroquinoxalinamine derivative, is able to rescue cell death induced by *Gpx4* knockout [15]. Liproxstatin-1 suppressed cell death induced by ferroptosis inducers (erastin, RSL3, and BSO), but did not rescue cells dying by apoptosis or necroptosis, indicating that liproxstatin-1 is a specific inhibitor of ferroptosis. When liproxstatin-1 was administered to mice with inducible loss of *Gpx4* protein, it delayed the acute renal failure caused by *Gpx4* depletion, and extended survival of mice compared to a vehicle-treated

group [15]. These results reinforce the susceptibility of kidney tissue to ferroptosis and suggest the value of ferroptosis inhibitors to ameliorate kidney injury [59].

Huntington disease

Huntington disease is an inherited neurodegenerative disorder caused by expansion of CAG repeats in the *Huntingtin (HTT)* gene [60]. While the mechanism by which mutant *HTT* induces the disease phenotype is not completely understood, it is known that the toxic effect of mutant *HTT* is functionally associated with glutamate-induced toxicity, glutathione-mediated redox regulation, and cellular iron metabolism [61, 62]. Lipid peroxidation products co-localized with mutant *Htt* inclusions in striatal neurons of R6/2 Huntington disease model mice [63]. Intraventricular delivery of deferoxamine, an iron chelator, provided a protective effect in R6/2 mice [64]. When ferrostatin-1 was added to rat corticostriatal brain slices, it prevented neuronal cell death induced by the gene delivery of *HTT* exon 1 fragment with a pathogenic repeat (73Q) [57]. Taken together, the data support the hypothesis that ferroptosis plays a detrimental role in the context of Huntington disease.

Periventricular leukomalacia

Periventricular leukomalacia (PVL) is a form of white-matter brain injury that underlies most of the neurologic morbidity encountered by many premature infants [65]. At the cellular level, it is caused by loss of oligodendrocytes (OLs), which are particularly vulnerable to neuronal cell death during the trauma of premature birth, contributing to the neuropathogenesis of PVL. Analysis of patient samples demonstrated the presence of abundant lipid oxidation products, such as 8-isoprostane and malondialdehyde (MDA) in the cerebrospinal fluid of infants with white matter injuries [66]. Glutathione depletion in rat OLs cultures induced cell death that was prevented by vitamin E co-treatment [67]. Ferrostatin-1 and its analogs also protected OLs from death by glutathione depletion, suggesting that the ferroptosis pathway is involved in this form of brain injury [57].

SBP2 deficiency syndrome

Selenocysteine insertion sequence binding protein 2 (SECISBP2; SBP2) binds to a stem loop RNA structure (Sec insertion sequence [SECIS] element) located in 3'-UTR region of selenoprotein mRNAs, and facilitates the incorporation of tRNA(Sec) into the ribosomal complex at the internal UGA site [68]. Patients with mutations in the *SBP2* gene have been identified who have reduced amounts of most selenoproteins and displayed a multiple-symptom disorder [69, 70, 71, 72]. These patients displayed high susceptibility to UV-radiation-induced oxidative damage, which is explained by deficiency in the synthesis of glutathione peroxidases. Dermal fibroblasts from the patients generated markedly increased lipid-ROS compared to control cells, as assessed by BODIPY-C11 staining, suggesting that ferroptosis might also be activated in this context.

Cancer

The possibility of applying ferroptosis inducers to RAS-mutated cancer cells has been investigated by testing erastin in 117 cancer cell lines from diverse tissues [24]. Although erastin displayed selective lethality in engineered cells overexpressing *HRAS*^{G12V}, there

was no consistent difference in erastin sensitivity between wild-type and mutated RAS cells. Relevant to this, ectopic overexpression of oncogenic RAS mutants increased basal ROS levels in fibroblasts, through a RAF-MEK-MAPK-NOX pathway, whereas mutations in the endogenous RAS alleles (without overexpression) upregulated NRF2, a transcription factor that induces expression of antioxidant genes, enhancing the ROS-detoxifying capacity of the cells [73]. The RAS-selective-lethal property of ferroptosis inducers might be masked in RAS-mutated cancer cell lines due to activated NRF2. Consistent with this hypothesis is the report that NRF2 protects against ferroptosis in hepatocellular carcinoma cells [74].

A recent study reported that p53 can activate ferroptosis by suppressing the expression of SLC7A11, a component of system x_c^- [75]. Furthermore, this suppression was suggested to contribute to the tumor suppressive activity of p53, indicating that p53 wild-type tumors may be susceptible to treatment with ferroptosis inducers that inhibit system x_c^- .

Diffuse large B cell lymphoma (DLBCL) and renal cell carcinomas (RCC) may be effectively targeted with ferroptosis inducers. DLBCLs are intrinsically more sensitive to ferroptosis compared to other subtypes of hematologic cancer, such as acute myeloid leukemia and multiple myeloma. Since some leukemias and lymphomas have a defective transsulfuration pathway [76, 77], which increases their dependence on cysteine/cystine import from the extracellular environment, a cysteine/cystine auxotrophy could partially explain the general sensitivity of DLBCL to ferroptosis by system x_c^- inhibition. Furthermore, DLBCLs with low system x_c^- activity are more susceptible to ferroptosis, as sulfasalazine potently inhibited the growth of lymphomas with low-level expression of SLC7A11, a subunit of system x_c^- [77, 78]. Furthermore, *SLC7A11*-deficient mice develop normally and are healthy [79] suggesting that compounds targeting system x_c^- with high specificity may likely have minimal side effects under pre-clinical and clinical settings.

Moreover, RCC was found to be particularly susceptible to erastin-induced ferroptosis compared to other tissues in the NCI-60 panel, a panel of cancer cell lines derived from eight different tissues [24]. There are three subtypes of RCCs based on histological classification: clear cell, papillary, and chromophobe RCCs. Chromophobe RCCs can be differentiated from other RCCs based on the intense iron staining in the tumor tissue [80]. In addition, iron consumption by renal cell carcinoma has been considered as the cause of iron deficiency related anemia in patients [81, 82]. In cell culture models, the addition of iron to culture media sensitizes cancer cells to ferroptosis, probably by lowering the threshold to initiate oxidative damage [10]. The iron-enriched tumor environment as well as the use of sorafenib to treat renal cell carcinomas in the clinic suggest that RCCs, especially chromophobe RCCs, could be targeted for ferroptosis induction. Improved erastin analogs, such as piperazine erastin (PE) [24] and imidazole ketone erastin (IKE) [83] may be useful as in vivo probes of tumor susceptibility to ferroptosis. Of note, artemisinin derivatives have been reported to induce iron-dependent cell death, and specifically ferroptosis, suggesting they may also be of use in treating such iron-replete tumors [84, 85].

Concluding remarks

An unbiased analysis of cell death pathways has revealed the existence of a previously unappreciated form of regulated cell death—ferroptosis. Several lines of evidence suggest that ferroptosis inducers are not simple oxidizers that, in conjunction with cellular iron, stimulate massive oxidation of biomolecules in the cells, similar to those generated by H₂O₂. First, ferroptosis inducers lack an obvious chemical moiety with redox activity. Second, inhibitors of ferroptosis suppress lethality of erastin and RSL3, but do not suppress other oxidative lethal agents, including H₂O₂, phenylarsine oxide (a general oxidizer of thiol group), and rotenone (which generates reactive oxygen species at mitochondria). If ferroptosis inducers were acting as simple iron-dependent pro-oxidants like H₂O₂, they would not be specifically suppressed by inhibitors of ferroptosis. The unique nature of GPX4-regulated ferroptosis relative to simple oxidative biocides may be further clarified through the questions outlined in Outstanding Questions.

The role of iron remains elusive despite the specific requirement for a cellular iron pool during ferroptosis. Iron acts as a catalyst in converting peroxides into free radicals, such as hydroxyl and hydroperoxyl radicals. It was speculated that such Fenton chemistry might account for the lethal effect of ferroptosis inducers; however, the current view favors a more biological route of iron-mediated lipid peroxide generation; copper (Cu²⁺) and cobalt (Co²⁺) are known to catalyze Fenton chemistry, but these metals do not sensitize cells to ferroptosis, whereas iron does [10]. Moreover, the free radicals generated by Fenton chemistry are highly reactive to biomolecules and induce nonspecific, massive oxidative damage to cells, which is not consistent with the regulated nature of ferroptosis. It is likely that iron-containing enzymes that are associated with lipid redox regulation are activated during ferroptosis. A candidate family of enzymes with this property is the family of lipoxygenases that catalyze the dioxygenation of polyunsaturated fatty acids in lipids [86]. In addition, the iron-containing heme oxygenase-1 (HO-1) was reported to be induced upon erastin treatment and to accelerate erastin-induced ferroptosis[87]; thus, HO-1 may be a source of iron driving the lipid peroxidation that occurs during ferroptosis, at least in response to erastin.

The biological significance of ferroptosis is expanding rapidly by virtue of the discovery that GPX4 and system x_c⁻ are crucial regulators of ferroptosis, as well as the use of ferrostatins to inhibit ferroptosis in diverse contexts. Intriguing questions remain that need to be addressed to improve our understanding of ferroptosis (see Outstanding Questions). Answers to these and other questions will further illuminate the ferroptotic cell death pathway, and should be instrumental in translating our knowledge of this basic cell biology to clinical settings.

Acknowledgement

We thank Arie Zask for his critical reading of the manuscript. This work was supported by the Howard Hughes Medical Institute, National Institute of Health (5R01CA097061, 5R01GM085081, R01CA161061), and New York Stem Cell Science (C026715) to B.R.S. Brent R. Stockwell is an Early Career Scientist of the Howard Hughes Medical Institute.

References

1. Linkermann A, et al. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. *Nat Rev Immunol*. 2014; 14:759–767. [PubMed: 25324125]
2. Galluzzi L, et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. *Cell Death Differ*. 2015; 22:58–73. [PubMed: 25236395]
3. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. *Nature*. 2015; 517:311–320. [PubMed: 25592536]
4. Lane, N. *Oxygen : the molecule that made the world*. Oxford University Press; 2002.
5. Boenigk, J., et al. *Biodiversity and Earth History*. Springer-Verlag; 2015.
6. Lyons TW, et al. The rise of oxygen in Earth's early ocean and atmosphere. *Nature*. 2014; 506:307–315. [PubMed: 24553238]
7. Pratt DA, et al. Free radical oxidation of polyunsaturated lipids: New mechanistic insights and the development of peroxy radical clocks. *Acc Chem Res*. 2011; 44:458–467. [PubMed: 21486044]
8. Lombard J, et al. The early evolution of lipid membranes and the three domains of life. *Nat Rev Microbiol*. 2012; 10:507–515. [PubMed: 22683881]
9. Hulbert AJ, et al. Polyunsaturated fats, membrane lipids and animal longevity. *J Comp Physiol B*. 2014; 184:149–166. [PubMed: 24129945]
10. Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell*. 2012; 149:1060–1072. [PubMed: 22632970]
11. Dolma S, et al. Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell*. 2003; 3:285–296. [PubMed: 12676586]
12. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. *Chem Biol*. 2008; 15:234–245. [PubMed: 18355723]
13. Yagoda N, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. *Nature*. 2007; 447:864–868. [PubMed: 17568748]
14. Wolpaw AJ, et al. Modulatory profiling identifies mechanisms of small molecule-induced cell death. *Proc Natl Acad Sci U S A*. 2011; 108:E771–E780. [PubMed: 21896738]
15. Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. *Nat Cell Biol*. 2014; 16:1180–1191. [PubMed: 25402683]
16. Zhou W, Yuan J. Necroptosis in health and diseases. *Semin Cell Dev Biol*. 2014; 35:14–23. [PubMed: 25087983]
17. Root DE, et al. Biological mechanism profiling using an annotated compound library. *Chem Biol*. 2003; 10:881–892. [PubMed: 14522058]
18. Wolpaw AJ, Stockwell BR. Multidimensional profiling in the investigation of small-molecule-induced cell death. *Methods Enzymol*. 2014; 545:265–302. [PubMed: 25065894]
19. Mehta A, et al. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. *Eur J Pharmacol*. 2013; 698:6–18. [PubMed: 23123057]
20. Bridges RJ, et al. System xc(–) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. *Br J Pharmacol*. 2012; 165:20–34. [PubMed: 21564084]
21. Bannai S, Kitamura E. Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture. *J Biol Chem*. 1980; 255:2372–2376. [PubMed: 7358676]
22. Tan S, et al. Oxytosis: A novel form of programmed cell death. *Curr Top Med Chem*. 2001; 1:497–506. [PubMed: 11895126]
23. Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. *Nat Chem Biol*. 2014; 10:9–17. [PubMed: 24346035]
24. Yang WS, et al. Regulation of ferroptotic cancer cell death by Gpx4. *Cell*. 2014; 156:317–331. [PubMed: 24439385]
25. Brigelius-Flohe R, Maiorino M. Glutathione peroxidases. *Biochim Biophys Acta*. 2013; 1830:3289–3303. [PubMed: 23201771]

26. Weiwer M, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. *Bioorg Med Chem Lett*. 2012; 22:1822–1826. [PubMed: 22297109]
27. Louandre C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. *Int J Cancer*. 2013; 133:1732–1742. [PubMed: 23505071]
28. Lachaier E, et al. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors. *Anticancer Res*. 2014; 34:6417–6422. [PubMed: 25368241]
29. Dixon SJ, et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *Elife*. 2014; 3:e02523. [PubMed: 24844246]
30. Louandre C, et al. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. *Cancer Lett*. 2015; 356:971–977. [PubMed: 25444922]
31. Shimada K, et al. Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis. *Nat Chem Biol*. 2015 under review.
32. Dixon SJ, et al. Human Haploid Cell Genetics Reveals Roles for Lipid Metabolism Genes in Nonapoptotic Cell Death. *ACS Chem Biol*. 2015; 10:1604–1609. [PubMed: 25965523]
33. Kryukov GV, et al. Characterization of mammalian selenoproteomes. *Science*. 2003; 300:1439–1443. [PubMed: 12775843]
34. Warner GJ, et al. Inhibition of selenoprotein synthesis by selenocysteine tRNA[Ser]^{Sec} lacking isopentenyladenosine. *J Biol Chem*. 2000; 275:28110–28119. [PubMed: 10821829]
35. McBean GJ. The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. *Amino Acids*. 2012; 42:199–205. [PubMed: 21369939]
36. McBean GJ. Cerebral cystine uptake: a tale of two transporters. *Trends Pharmacol Sci*. 2002; 23:299–302. [PubMed: 12119142]
37. Hayano M, et al. Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation. *Cell Death Differ*. 2015 Jul 17.
38. Gao M, et al. Glutaminolysis and Transferrin Regulate Ferroptosis. *Mol Cell*. 2015; 59:298–308. [PubMed: 26166707]
39. Gao M, et al. Metabolism and iron signaling in ferroptotic cell death. *Oncotarget*. 2015 Sep 15.
40. Lorincz T, et al. Ferroptosis is Involved in Acetaminophen Induced Cell Death. *Pathol Oncol Res*. 2015; 21:1115–1121. [PubMed: 25962350]
41. Sun X, et al. HSPB1 as a novel regulator of ferroptotic cancer cell death. *Oncogene*. 2015 Mar 2.
42. Imai H, et al. Early embryonic lethality caused by targeted disruption of the mouse PHGPx gene. *Biochem Biophys Res Commun*. 2003; 305:278–286. [PubMed: 12745070]
43. Yant LJ, et al. The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults. *Free Radic Biol Med*. 2003; 34:496–502. [PubMed: 12566075]
44. Seiler A, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. *Cell Metab*. 2008; 8:237–248. [PubMed: 18762024]
45. Chen L, et al. Ablation of ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. *J Biol Chem*. 2015 Sep 23.
46. Matsushita M, et al. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. *J Exp Med*. 2015; 212:555–568. [PubMed: 25824823]
47. Ren D, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. *Science*. 2010; 330:1390–1393. [PubMed: 21127253]
48. Schnabel D, et al. Expression and regulation of antioxidant enzymes in the developing limb support a function of ROS in interdigital cell death. *Dev Biol*. 2006; 291:291–299. [PubMed: 16445905]
49. Ran Q, et al. Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stress-induced apoptosis. *J Biol Chem*. 2004; 279:55137–55146. [PubMed: 15496407]
50. Lindsten T, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. *Mol Cell*. 2000; 6:1389–1399. [PubMed: 11163212]

51. Homma T, Fujii J. Application of glutathione as anti-oxidative and anti-aging drugs. *Curr Drug Metab.* 2015 Oct 15.
52. Aygun C, et al. Simplified gyral pattern with cerebellar hypoplasia in Sedaghatian type spondylometaphyseal dysplasia: a clinical report and review of the literature. *Am J Med Genet A.* 2012; 158A:1400–1405. [PubMed: 22529034]
53. Smith AC, et al. Mutations in the enzyme glutathione peroxidase 4 cause Sedaghatian-type spondylometaphyseal dysplasia. *J Med Genet.* 2014; 51:470–474. [PubMed: 24706940]
54. Bosch X, et al. Rhabdomyolysis and acute kidney injury. *N Engl J Med.* 2009; 361:62–72. [PubMed: 19571284]
55. Bouteau O, Roberts LJ 2nd. Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. *Free Radic Biol Med.* 2011; 51:1062–1067. [PubMed: 21034813]
56. Zager RA, et al. Ceramide accumulation during oxidant renal tubular injury: mechanisms and potential consequences. *J Am Soc Nephrol.* 1998; 9:1670–1680. [PubMed: 9727376]
57. Skouta R, et al. Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. *J Am Chem Soc.* 2014; 136:4551–4556. [PubMed: 24592866]
58. Linkermann A, et al. Synchronized renal tubular cell death involves ferroptosis. *Proc Natl Acad Sci U S A.* 2014; 111:16836–16841. [PubMed: 25385600]
59. Sancho-Martinez SM, et al. Pathophysiological role of different tubular epithelial cell death modes in acute kidney injury. *Clin Kidney J.* 2015; 8:548–559. [PubMed: 26413280]
60. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol.* 2011; 10:83–98. [PubMed: 21163446]
61. Johnson WM, et al. Dysregulation of glutathione homeostasis in neurodegenerative diseases. *Nutrients.* 2012; 4:1399–1440. [PubMed: 23201762]
62. Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. *J Neurochem.* 2014; 130:328–350. [PubMed: 24717009]
63. Sadagurski M, et al. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. *J Clin Invest.* 2011; 121:4070–4081. [PubMed: 21926467]
64. Chen J, et al. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. *PLoS One.* 2013; 8:e77023. [PubMed: 24146952]
65. Volpe JJ. Neurobiology of periventricular leukomalacia in the premature infant. *Pediatr Res.* 2001; 50:553–562. [PubMed: 11641446]
66. Inder T, et al. Elevated free radical products in the cerebrospinal fluid of VLBW infants with cerebral white matter injury. *Pediatr Res.* 2002; 52:213–218. [PubMed: 12149498]
67. Back SA, et al. Maturation-dependent vulnerability of oligodendrocytes to oxidative stress-induced death caused by glutathione depletion. *J Neurosci.* 1998; 18:6241–6253. [PubMed: 9698317]
68. Donovan J, Copeland PR. Threading the needle: getting selenocysteine into proteins. *Antioxid Redox Signal.* 2010; 12:881–892. [PubMed: 19747061]
69. Dumitrescu AM, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. *Nat Genet.* 2005; 37:1247–1252. [PubMed: 16228000]
70. Azevedo MF, et al. Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene. *J Clin Endocrinol Metab.* 2010; 95:4066–4071. [PubMed: 20501692]
71. Schoenmakers E, et al. Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. *J Clin Invest.* 2010; 120:4220–4235. [PubMed: 21084748]
72. Hamajima T, et al. Novel compound heterozygous mutations in the SBP2 gene: characteristic clinical manifestations and the implications of GH and triiodothyronine in longitudinal bone growth and maturation. *Eur J Endocrinol.* 2012; 166:757–764. [PubMed: 22247018]
73. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. *Nature.* 2011; 475:106–109. [PubMed: 21734707]
74. Sun X, et al. Activation of the p62-Keap1-NRF2 Pathway Protects against Ferroptosis in Hepatocellular Carcinoma Cells. *Hepatology.* 2015
75. Jiang L, et al. Ferroptosis as a p53-mediated activity during tumour suppression. *Nature.* 2015; 520:57–62. [PubMed: 25799988]

76. Iglehart JK, et al. Cystine requirement of continuous human lymphoid cell lines of normal and leukemic origin. *J Biol Chem.* 1977; 252:7184–7191. [PubMed: 903356]
77. Gout PW, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug. *Leukemia.* 2001; 15:1633–1640. [PubMed: 11587223]
78. Gout PW, et al. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. *Anticancer Drugs.* 2003; 14:21–29. [PubMed: 12544255]
79. Sato H, et al. Redox imbalance in cystine/glutamate transporter-deficient mice. *J Biol Chem.* 2005; 280:37423–37429. [PubMed: 16144837]
80. Tickoo SK, et al. Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. *Am J Surg Pathol.* 1998; 22:419–424. [PubMed: 9537468]
81. Kroll MH, et al. Microcytic hypochromic anemia associated with renal cell carcinoma. *South Med J.* 1984; 77:635–637. [PubMed: 6719167]
82. Dowd AA, et al. Renal cell carcinoma as a cause of iron deficiency anemia. *African Journal of Urology.* 2014; 20:25–27.
83. Larraufie MH, et al. Incorporation of metabolically stable ketones into a small molecule probe to increase potency and water solubility. *Bioorg Med Chem Lett.* 2015 Jul 14.
84. Ooko E, et al. Artemisinin derivatives induce iron-dependent cell death (ferroptosis) in tumor cells. *Phytomedicine.* 2015; 22:1045–1054. [PubMed: 26407947]
85. Eling N, et al. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. *Oncoscience.* 2015; 2:517–532. [PubMed: 26097885]
86. Haeggstrom JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. *Chem Rev.* 2011; 111:5866–5898. [PubMed: 21936577]
87. Kwon MY, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. *Oncotarget.* 2015; 6:24393–24403. [PubMed: 26405158]
88. Murphy TH, et al. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. *Neuron.* 1989; 2:1547–1558. [PubMed: 2576375]
89. Zaman K, et al. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. *J Neurosci.* 1999; 19:9821–9830. [PubMed: 10559391]
90. Reuther C, et al. The serine protease inhibitor TLCK attenuates intrinsic death pathways in neurons upstream of mitochondrial demise. *Apoptosis.* 2014; 19:1545–1558. [PubMed: 25146045]
91. Zhang Y, Bhavnani BR. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. *BMC Neurosci.* 2006; 7:49. [PubMed: 16776830]
92. Li Y, et al. Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. *Proc Natl Acad Sci U S A.* 1998; 95:7748–7753. [PubMed: 9636222]
93. Fukui M, et al. Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells. *Eur J Pharmacol.* 2009; 617:1–11. [PubMed: 19580806]

Trends box

- Ferroptosis is a regulated, non-apoptotic form of cell death distinct from other cell death modalities
- Loss of GPX4 activity and subsequent accumulation of lipid hydroperoxides executes ferroptosis
- Diffuse large B cell lymphomas and renal cell carcinomas are particularly susceptible to GPX4-regulated ferroptosis
- Inhibition of ferroptosis may represent a promising therapeutic approach for treating pathological conditions such as acute kidney injury

Box 1. Cell death pathways in glutamate-induced neurotoxicity

When excessive glutamate is present near nerve cells, a non-apoptotic, oxidative form of cell death occurs. As excessive amount of glutamate inhibit system x_c^- , a cystine/ glutamate antiporter; it is likely that glutamate-induced neurotoxicity displays many features of ferroptosis. Indeed, nerve cells treated with glutamate show decreased cystine import, become deficient in cellular glutathione, and undergo oxidative cell death that can be prevented by iron chelation [22, 88, 89]. The term oxytosis has been used to describe this mode of neuronal cell death [22]. Although oxytosis and ferroptosis display related phenotypes, there exist several notable differences. During oxytosis, high level of calcium ions (Ca^{2+}) enter cells and activate a number of destructive enzymes such as serine proteases, calpains, and phospholipases [90, 91, 92]. The elevated calcium ions also damage mitochondria, causing translocation of AIF (apoptosis-inducing factor) from mitochondria to nucleus [93]. These biochemical changes are required for executing oxytosis, whereas they are dispensable for ferroptosis. Oxytosis may represent a combination of the more general ferroptosis and a specialized type of damage induced by glutamate through other pathways and receptors.

Normally, glutamate acts a signaling molecule (neurotransmitter) that mediates the majority of excitatory synaptic transmissions in the central nervous system. This glutamate-mediated signaling occurs through the interactions between glutamate and glutamate receptors in nerve cells. It is possible that this glutamate to glutamate-receptor interaction plays significant roles in oxytosis in nerve cells, whereas inhibition of system x_c^- plays a dominant role in ferroptosis in cancer cells (see Figure I). VDCCs =voltage dependent calcium channels.

Outstanding questions

- What is the specific role of iron during ferroptosis?
- What is the structural basis of GPX4 inhibition by (1S, 3R)-RSL3 and related compounds?
- What are the specific lipid subclasses that are oxidized during ferroptosis?
- What are the molecular downstream pathways after generation of oxidized lipids during ferroptosis?
- What is the best predictive biomarker or signature for ferroptosis sensitivity?
- What is the role of ferroptosis in other biological processes?

Figure 1.

Key Figure. Molecular pathways of ferroptosis regulation. Small molecule inducers of ferroptosis are colored red, whereas small molecule inhibitors of ferroptosis are colored blue. TS pathway = transsulfuration pathway; Se = Selenocysteine; DFO = deferoxamine; CPX = ciclopirox olamine; CoQ₁₀ = Coenzyme Q₁₀.

Figure I.
Cell death pathways in glutamate-induced neurotoxicity

Table 1

Ferroptosis in pathological conditions

Diffuse large B cell lymphoma (DLBCL)	Intrinsically more sensitive to ferroptosis inducers [16] Dependent on cysteine/cystine import system (system x_c^-) due to defective transsulfuration pathway in DLBCL [58, 59]
Chromophobe renal cell carcinoma	Intense iron staining in the tumor tissue (iron rich environment) [61]
Acute kidney failure by rhabdomyolysis	Ferrostatin-1 prevented cell death in an ex vivo model of rhabdomyolysis-induced acute kidney injury [40] Myolysis releases myoglobin and heme iron causing ROS generation and acute kidney injury [38]
Acute kidney failure by ischemia-reperfusion injury	16–86, a third generation ferrostatin, protected mice from acute renal failure due to ischemia-reperfusion injury [41]
Huntington's disease	Ferrostatin-1 prevented cell death in an organotypic slice culture model of Huntington's disease [40]
Periventricular Leukomalacia (PVL)	Lipid peroxidation products detected in 33 human autopsy brains with PVL [47] Premature oligodendrocytes (OLs) were more sensitive to GSH depletion-induced cell death [49] Ferrostatin-1 prevented cell death in an OL culture model of PVL [40]
SBP2 deficiency syndrome	Mutation in SBP2 prevents translation of selenoproteins including GPX4 [53] Fibroblasts from patients showed increased basal level of lipid-ROS [53]
Sedaghatian-type spondylometaphyseal dysplasia	Loss of function mutation in GPX4 is associated with neonatal lethality of affected children [36]